Durect concludes enrolment in PERSIST trial of non-opioid analgesic

US-based biopharmaceutical company Durect has concluded patient enrolment in its Phase III PERSIST clinical trial of Posimir (Saber-Bupivacaine) for pain relief following surgery.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news